SG11201903064SA - Arsenic compositions - Google Patents
Arsenic compositionsInfo
- Publication number
- SG11201903064SA SG11201903064SA SG11201903064SA SG11201903064SA SG11201903064SA SG 11201903064S A SG11201903064S A SG 11201903064SA SG 11201903064S A SG11201903064S A SG 11201903064SA SG 11201903064S A SG11201903064S A SG 11201903064SA SG 11201903064S A SG11201903064S A SG 11201903064SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- courallie
- english
- pct
- arsenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 June 2018 (07.06.2018) WI P0 I P C T onion °nolo III 1101 Immo Elio oimIE (10) International Publication Number WO 2018/098519 Al (51) International Patent Classification: A61K 33/36 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/AU2017/050807 (22) International Filing Date: 02 August 2017 (02.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2016904945 01 December 2016 (01.12.2016) AU (71) Applicant: EUPHARMA PTY LTD [AU/AU]; 16 Courallie Road, Northbridge, New South Wales 2063 (AU). (72) Inventor: EUTICK, Malvin; 16 Courallie Road, North- bridge, New South Wales 2063 (AU). (74) Agent: FISHER ADAMS KELLY CALLINANS; Level 6, 175 Eagle Street, Brisbane, Queensland 4000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: ARSENIC COMPOSITIONS 4 t 4 6 ,50 Pas4ion ral 0.67762 cc cc O C FIG 1 (57) : The present invention is predicated on the realisation that problems with the poor water solubility of arsenic trioxide and the extreme difficulty in dissolving arsenic trioxide in anything other than a very basic solution, could be overcome by forming a much more soluble diarsenic tetraoxide, including the compound NaHAs2O4, prior to its delivery to a patient. Pharmaceutical compositions with such compounds and their use in the treatment of cancers is disclosed.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016904945A AU2016904945A0 (en) | 2016-12-01 | Arsenic compositions | |
| PCT/AU2017/050807 WO2018098519A1 (en) | 2016-12-01 | 2017-08-02 | Arsenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903064SA true SG11201903064SA (en) | 2019-05-30 |
Family
ID=62240940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903064SA SG11201903064SA (en) | 2016-12-01 | 2017-08-02 | Arsenic compositions |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11241453B2 (en) |
| EP (1) | EP3548044B1 (en) |
| JP (2) | JP7080230B2 (en) |
| KR (1) | KR102487884B1 (en) |
| CN (1) | CN109952105A (en) |
| AU (1) | AU2017368444B9 (en) |
| BR (1) | BR112019007498A2 (en) |
| CA (1) | CA3041357A1 (en) |
| CL (1) | CL2019001422A1 (en) |
| DK (1) | DK3548044T3 (en) |
| ES (1) | ES2964979T3 (en) |
| IL (1) | IL265986B (en) |
| MX (1) | MX2019006107A (en) |
| NZ (1) | NZ752214A (en) |
| PE (1) | PE20191544A1 (en) |
| PL (1) | PL3548044T3 (en) |
| SG (1) | SG11201903064SA (en) |
| TW (1) | TWI808060B (en) |
| WO (1) | WO2018098519A1 (en) |
| ZA (1) | ZA201902156B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017305945B2 (en) | 2016-08-01 | 2019-11-21 | Veolia Water Solutions & Technologies Support | Process for removing silica from produced water and other wastewater streams |
| AU2017368444B9 (en) * | 2016-12-01 | 2020-07-02 | Eupharma Pty Ltd | Arsenic compositions |
| CA3211092A1 (en) * | 2021-02-26 | 2022-09-01 | Intas Pharmaceuticals Ltd. | Oral pharmaceutical composition of arsenic trioxide |
| JP2022151442A (en) * | 2021-03-26 | 2022-10-07 | 均 石井 | Agents for treating leukemia |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2080004A (en) * | 1933-05-17 | 1937-05-11 | Frederick E Dearborn | Double salt of copper arsenite and a copper salt of an unsaturated fatty acid and process of making the same |
| US3280046A (en) | 1963-03-27 | 1966-10-18 | Dow Chemical Co | Polyol ether resins and utility |
| CA2307208A1 (en) | 1997-10-15 | 1999-04-22 | Polarx Biopharmaceuticals, Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| ES2399480T3 (en) | 1997-11-10 | 2013-04-01 | Memorial Sloan-Kettering Cancer Center | Production process of arsenic trioxide formulations |
| CN1471925A (en) * | 2002-08-02 | 2004-02-04 | 丛繁滋 | Arsenic contained composition for directly hard tumour medoicine feed, preparation, preparing method thereof |
| US7521071B2 (en) | 2002-10-09 | 2009-04-21 | Versitech Limited | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US20090246291A1 (en) * | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
| CN102060722B (en) * | 2009-05-01 | 2014-06-11 | 常州高新技术产业开发区三维工业技术研究所有限公司 | Arsenic compound and preparation method and use thereof |
| EP2359812A1 (en) | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
| CN105435228B (en) * | 2014-08-14 | 2020-08-07 | 中国科学院上海营养与健康研究所 | New anti-tumor application of arsenic trioxide and anti-tumor preparation |
| ES2954081T3 (en) | 2015-01-29 | 2023-11-20 | Eupharma Pty Ltd | Compositions containing arsenic for use in treatment methods |
| EP3981414A1 (en) | 2015-02-01 | 2022-04-13 | Syros Pharmaceuticals, Inc. | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
| AU2017368444B9 (en) | 2016-12-01 | 2020-07-02 | Eupharma Pty Ltd | Arsenic compositions |
-
2017
- 2017-08-02 AU AU2017368444A patent/AU2017368444B9/en active Active
- 2017-08-02 DK DK17876251.4T patent/DK3548044T3/en active
- 2017-08-02 JP JP2019524985A patent/JP7080230B2/en active Active
- 2017-08-02 KR KR1020197013881A patent/KR102487884B1/en active IP Right Grant
- 2017-08-02 MX MX2019006107A patent/MX2019006107A/en unknown
- 2017-08-02 US US16/465,693 patent/US11241453B2/en active Active
- 2017-08-02 SG SG11201903064SA patent/SG11201903064SA/en unknown
- 2017-08-02 PL PL17876251.4T patent/PL3548044T3/en unknown
- 2017-08-02 WO PCT/AU2017/050807 patent/WO2018098519A1/en unknown
- 2017-08-02 NZ NZ752214A patent/NZ752214A/en unknown
- 2017-08-02 CA CA3041357A patent/CA3041357A1/en active Pending
- 2017-08-02 ES ES17876251T patent/ES2964979T3/en active Active
- 2017-08-02 EP EP17876251.4A patent/EP3548044B1/en active Active
- 2017-08-02 PE PE2019000939A patent/PE20191544A1/en unknown
- 2017-08-02 TW TW106126050A patent/TWI808060B/en active
- 2017-08-02 CN CN201780069613.2A patent/CN109952105A/en active Pending
- 2017-08-02 IL IL265986A patent/IL265986B/en unknown
- 2017-08-02 BR BR112019007498A patent/BR112019007498A2/en active Search and Examination
-
2019
- 2019-04-05 ZA ZA2019/02156A patent/ZA201902156B/en unknown
- 2019-05-27 CL CL2019001422A patent/CL2019001422A1/en unknown
-
2022
- 2022-02-25 JP JP2022028046A patent/JP7419415B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3548044A4 (en) | 2020-07-22 |
| PE20191544A1 (en) | 2019-10-24 |
| KR20190089865A (en) | 2019-07-31 |
| ES2964979T3 (en) | 2024-04-10 |
| PL3548044T3 (en) | 2024-03-04 |
| AU2017368444B9 (en) | 2020-07-02 |
| IL265986B (en) | 2022-09-01 |
| AU2017368444A1 (en) | 2019-04-18 |
| TW201821087A (en) | 2018-06-16 |
| ZA201902156B (en) | 2021-01-27 |
| US20200016196A1 (en) | 2020-01-16 |
| TWI808060B (en) | 2023-07-11 |
| IL265986A (en) | 2019-06-30 |
| NZ752214A (en) | 2022-11-25 |
| AU2017368444B2 (en) | 2020-04-30 |
| JP7419415B2 (en) | 2024-01-22 |
| CN109952105A (en) | 2019-06-28 |
| KR102487884B1 (en) | 2023-01-11 |
| CL2019001422A1 (en) | 2019-08-02 |
| EP3548044A1 (en) | 2019-10-09 |
| CA3041357A1 (en) | 2018-06-07 |
| JP2020500845A (en) | 2020-01-16 |
| EP3548044B1 (en) | 2023-09-20 |
| US11241453B2 (en) | 2022-02-08 |
| DK3548044T3 (en) | 2023-12-11 |
| MX2019006107A (en) | 2019-08-21 |
| JP7080230B2 (en) | 2022-06-03 |
| JP2022069485A (en) | 2022-05-11 |
| WO2018098519A1 (en) | 2018-06-07 |
| BR112019007498A2 (en) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201903064SA (en) | Arsenic compositions | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201806127XA (en) | Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate | |
| SG11201906682YA (en) | Glucagon receptor binding proteins and methods of use thereof |